Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Texas Oncology, P.A.

Neither a doctor nor a teaching hospital

Research payments

$19,521,018

8,961 payments

Through program year 2025, Texas Oncology, P.A. is reported as receiving $19,521,018 in research payments, across 8,961 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $451,792 322
2024 Research $1,431,893 212
2023 Research $4,946,069 469
2022 Research $3,738,194 695
2021 Research $1,747,928 352
2020 Research $2,875,459 3,596
2019 Research $4,329,683 3,315

Breakdown

Who paid Research payments · program years 2019–2025
  1. BeiGene, Ltd. $7,787,944 490 payments
  2. Merck Sharp & Dohme Corporation $5,748,271 6,227 payments
  3. Genentech, Inc. $1,233,280 81 payments
  4. Amgen Inc. $1,230,195 69 payments
  5. Exelixis Inc. $1,007,514 189 payments
  6. MorphoSys AG $580,150 590 payments
  7. Daiichi Sankyo Company LTD $383,947 48 payments
  8. Radius Health, Inc. $291,864 231 payments
  9. Celgene Corporation $238,481 34 payments
  10. Incyte Corporation $203,374 230 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib $3,731,578 50 payments
  2. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib $1,979,989 106 payments
  3. A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 $1,399,294 2,417 payments
  4. An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies $999,464 3 payments
  5. Prospective Observational Study of Onpro vs SOC $869,620 27 payments
  6. A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC $855,705 1,126 payments
  7. A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy $841,282 726 payments
  8. A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2 Breast Cancer KEYNOTE-756 $752,688 6 payments
  9. Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors $643,585 89 payments
  10. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients Wi $628,196 21 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record